Quest for Growth NV

PRESS & ANALYST MEETING

31 JULY 2026

Welcome

Steven
Levecke
Executive Officer
Unquoted Portfolio
pwc

Jan
Avonts
Quoted Portfolio
Leo Stevens

Jelle
Van de Putte

Fund Administrator
BNP PARIBAS ASSET MANAGEMENT

Team

Lieve
Creten

Chair

Jos
Peeters

Director

Thierry
François

Director

Paul
Van Dun

Director

Sabine
Vermassen

Director
Executive Officer

Véronique
Léonard

Director

Board of Directors

BoD reduced to six people. Thierry François replaces Philippe de Vicq & Jos Clijsters since AGM of 2026.

2026 HY results

Highlights

	Net Asset Value per share	Stock price	Discount
30/06/2026	5.86 EUR	2.99 EUR	49.0%
31/12/2025	7.05 EUR	4.19 EUR	40.5%

- € 6.9M net profit in Q2
- Strong recovery in Q2 reducing HY net loss to € -3.4M (HY 2025: € +3.8M)
- Quoted portfolio makes up loss of Q1 in Q2, non-quoted (direct and funds) also profitable in Q2
- New quoted investments: Krones, SP Group & Schott Pharma
- Investment in Fortino Ventures III (€ 2M committed), backing ambitious B2B SaaS and AI founders
- New indirect investments in Xyall & Oska Health (through Capricorn Healthtech Fund II), in Conxai & Rocsys (through Capricorn Digital Growth Fund) and in mkind, Polysense.ai & Birdsview.com (through Fortino Ventures III)
- Icometrix acquired by GE Healthcare in 2025, leading to € 2M distribution from Capricorn ICT Arkiv to QfG
- Capital reduction of € 1 per share paid out on March 23, 2026



2026 HY results

Added value per share, per segment



2026 HY results

In EUR	30/06/2026	30/06/2025
Revenues from investments in quoted equities	**911,294**	**1,858,003**
Revenues from investments in venture & growth capital	**-1,334,678**	**-498,007**
Revenues from investments in venture & growth funds	**-1,873,084**	**-3,383,430**
Net interest income / expenses	40,807	17,314
Net realised foreign exchange gains / losses	-878	1,645
Net unrealised foreign exchange gains / losses	-157	-211
Total revenues from investments	**-2,256,697**	**5,190,233**
Other operating income / loss	18,329	0
Total operating income / loss	**-2,238,368**	**5,190,233**
Management fee	-581,503	-741,495
Other operating expenses	-303,228	-349,962
Profit / Loss from operating activities	**-3,123,098**	**4,098,777**
Net finance expenses	-3,472	-654
Profit / Loss before income taxes	**-3,126,570**	**4,098,123**
Withholding tax expenses	-227,708	-268,548
Other income taxes	-29,381	-32,349
Profit / Loss for the period	**-3,383,659**	**3,797,226**



2026 Q2 results

In EUR	30/06/2026	30/06/2025
Revenues from investments in quoted equities	**6,675,166**	**7,194,920**
Revenues from investments in venture & growth capital	**400,881**	**-473,253**
Revenues from investments in venture & growth funds	**339,829**	**-2,255,843**
Net interest income / expenses	20,772	4,871
Net realised foreign exchange gains / losses	-667	-13,345
Net unrealised foreign exchange gains / losses	-1,111	-211
Total revenues from investments	**7,434,870**	**4,457,138**
Other operating income / loss	8,697	-663
Total operating income / loss	**7,443,567**	**4,456,475**
Management fee	-290,751	-370,747
Other operating expenses	-76,666	-58,004
Profit / Loss from operating activities	**7,076,150**	**4,027,723**
Net finance expenses	-2,803	-121
Profit / Loss before income taxes	**7,073,347**	**4,027,602**
Withholding tax expenses	-200,235	-237,088
Other income taxes	0	-32,349
Profit / Loss for the period	**6,873,112**	**3,758,165**



Long term performance

Shareholder return in the last 10 years

Source: Bloomberg

Share holding period return last 10 years (since 30/06/2016): -20.4%

Long term performance

Return on equity in the last 10 years



Result in relation to equity at the beginning of the financial year, taking into account dividends and capital increases or distributions.



NAV holding period return last 10 years (since 30/06/2016): +13.9%

Long term performance

Discount of the share price to the NAV per share in the last 10 years

Long term performance

Share price, NAV, and discount since 2022





Portfolio on 30/06/2026

Composition and market capitalisation





Quest FOR GROWTH

58.7%
Quoted equities

Cleantech

JENSEN	6.9%
ROBERTET GROUPE	2.7%
ANDRITZ	2.5%
BEIJER • ALMA	2.2%
Kingspan	2.1%
Thermador Groupe	1.9%
KRONES	1.8%
ARCADIS	1.8%
Total	**22.0%**

Digital

EVS	5.0%
cewe	4.3%
nedap	3.9%
DeLonghi	2.7%
init	2.5%
TKH GROUP	2.0%
NORBIT - explore more -	1.8%
B&C SPEAKERS	1.2%
mensch und maschine Software	1.0%
Total	**24.4%**

Health

Virbac	3.2%
HARVIA	2.9%
EQUASENS	2.9%
SP GROUP	2.3%
SCHOTT PHARMA	0.9%
Total	**12.3%**

QUOTED EQUITIES

Equity	Sector / Market	Number of shares	Buy/sells (number) since 31/12/2025	Currency	Share Price	Valuation in EUR	In % of Net Asset Value
Cleantech						**24,195,791**	
ANDRITZ	Wiener Börse	37,000	-7,000	EUR	75.60	2,797,200	2.55%
ARCADIS	Euronext Amsterdam	58,000	12,000	EUR	33.62	1,949,960	1.77%
BEIJER ALMA	OMX Stockholm	90,000		SEK	297.00	2,409,519	2.19%
JENSEN GROUP	Euronext Brussels	89,634	-33,742	EUR	84.80	7,600,963	6.92%
KINGSPAN	Euronext Dublin	29,000	-21,000	EUR	79.95	2,318,550	2.11%
KRONES	Deutsche Börse (Xetra)	18,000	18,000	EUR	112.20	2,019,600	1.84%
ROBERTET	Euronext Paris	3,700	-1,300	EUR	806.00	2,982,200	2.71%
THERMADOR	Euronext Paris	26,944	-5,000	EUR	78.60	2,117,798	1.93%
Digital						**26,829,109**	
B&C SPEAKERS	Borsa Italiana	119,854	-45,150	EUR	11.05	1,324,387	1.21%
CEWE STIFTUNG	Deutsche Börse (Xetra)	52,000	-10,360	EUR	91.10	4,737,200	4.31%
DE'LONGHI	Borsa Italiana	80,000	-30,000	EUR	37.14	2,971,200	2.70%
EVS	Euronext Brussels	200,327		EUR	27.35	5,478,943	4.99%
INIT INNOVATION	Deutsche Börse (Xetra)	58,652		EUR	46.40	2,721,453	2.48%
MENSCH UND MASCHINE	Deutsche Börse (Xetra)	30,000		EUR	35.70	1,071,000	0.97%
NEDAP	Euronext Amsterdam	45,000	-9,648	EUR	95.50	4,297,500	3.91%
NORBIT	Euronext Oslo	135,000		NOK	169.20	2,019,539	1.84%
TKH GROUP	Euronext Amsterdam	50,570	-20,000	EUR	43.66	2,207,886	2.01%
Health						**13,444,408**	
EQUASENS	Euronext Paris	92,759		EUR	34.50	3,200,186	2.91%
HARVIA	OMX Helsinki	77,052		EUR	41.60	3,205,363	2.92%
SCHOTT PHARMA	Deutsche Börse (Xetra)	55,838	55,838	EUR	17.30	965,997	0.88%
SP GROUP	OMX Copenhagen	48,000	48,000	DKK	402.00	2,581,612	2.35%
VIRBAC	Euronext Paris	10,500	-750	EUR	332.50	3,491,250	3.18%
						64,469,307	**58.68%**

Quoted Equities

Market environment





source: Bloomberg, Capricorn Partners

Quoted Equities

Market environment



source: Bloomberg, Capricorn Partners



Quoted Equities

Market environment





source: Pitchbook, Apollo Chief Economist

Quoted Equities

Market environment



source: Pitchbook, Apollo Chief Economist

Quoted Equities

Best & worst performing shares YTD





Source: Bloomberg, Capricorn Partners
* Since the day of the first purchase in Quest for Growth
QfG Quoted(e): estimate excluding costs and cash

Quoted Equities

Valuation (NTM P/E)



Source: Bloomberg, Capricorn Partners



Quoted Equities

Top 10 positions

company	country	activity	segment	ptf. entry	% NAV
Jensen Group	Belgium	Heavy-Duty Laundry Equipment	Cleantech	2016	6.9%
EVS	Belgium	Live Broadcasting Equipment	Digital	2022	5.0%
CEWE	Germany	Photo and Online Printing Services	Digital	2017	4.3%
NEDAP	Netherlands	Technological Solutions	Digital	2018	3.9%
Virbac	France	Animal Health	Health	2024	3.2%
Harvia	Finland	Heaters for Saunas	Health	2024	2.9%
Equasens	France	Software for Pharmacies	Health	2010	2.9%
Robertet	France	Natural Ingredients	Cleantech	2024	2.7%
De'Longhi	Italy	Automated Coffee	Digital	2025	2.7%
Andritz	Austria	Telecom, Building and Industrial Solutions	Cleantech	2024	2.6%

Quoted Equities

New entry since May

- Global market leader in Drug Containment and Drug Delivery Systems like prefillable syringes, cartridges, vials and ampoules for large pharmaceutical companies, biotechs and CDMOs.
- Destocking and normalisation of demand for mRNA vaccines weighed on the growth and profitability of SCHOTT Pharma and triggered a derisked medium term outlook. First signs of turnaround visible after a period of multiple derating
- Demand is driven by the shift to biologics, (auto)injectables and an aging global population
- Oligopolistic market with high entry barriers
- Market cap: ca. € 2.6B (IPO in september 2023)
- Portfolio entry: 2026

P/E	4y EPS CAGR	ROE	Debt ratio
16.7x	--%	22%	0.2x

source: P/E, ROE & debt ratio based on 12-month forward Bloomberg estimates at 30 June 2026

Quoted Equities

New entry

SCHOTT PHARMA

Every minute, around 30,000 people receive an injection packed in a SCHOTT Pharma product

02 - Who we are

Drug Containment Solutions
(around 23% HVS)

Drug Delivery Systems
(100% HVS)

Ampoules	Vials		Cartridges		Glass syringes	Polymer syringes
Core	Core	HVS*	Core	HVS*	HVS*	HVS*

*High Value Solutions

9 © SCHOTT Pharma, IR Factbook

Quoted Equities

New entry

SCHOTT PHARMA

Quest FOR GROWTH

We translate pharma megatrends into our business

Innovation

03 - Strategy

Current market developments along megatrends		SCHOTT Pharma ideally positioned with broadest portfolio in the industry
GLP-1	Taking off, further applications emerging	Prefillable glass syringes, (RTU) cartridges
mRNA	Huge potential including and beyond vaccines	Prefillable polymer syringes, RTU vials
ADCs	Personalized cancer therapies based on antibodies	Specialty vials, i.e., coated (RTU) vials like EVERIC® lyo (former SCHOTT TopLyo®).
SubQ	Intravenous to subcutaneous: cost and time efficiency	Prefillable glass and polymer syringes, (RTU) cartridges
Homecare	Increased patient comfort, lower healthcare costs	Large-volume prefillable glass and polymer syringes, (RTU) cartridges
Manufacturing shift	Shift to RTU, supported by regulation	Extensive RTU portfolio: vials, cartridges, glass and polymer syringes
Sustainability	Transition towards more sustainable processes	Closed-loop recycling of pharmaceutical bulk trays, FIOLAX® Pro, and optimized RTU nests with significant lower waste

Quoted Equities

New entry since February

SP GROUP

- Leading supplier of custom polymer produced items for the Healthcare sector, Cleantech applications and several Industrial end markets
- M&A: Ide-Pro offers synergies for topline and cost structure
- Increasing share of own products (+/- 27%) together with efficiencies will further improve margins
- Market cap: ca. € 640M
- Portfolio entry: 2026

P/E	4y EPS CAGR	ROE	Debt ratio
11.4x	8%	19%	1.9x

source: P/E, ROE & debt ratio based on 12-month forward Bloomberg estimates at 30 June 2026

Quoted Equities

New entry

SP GROUP

Outlook for 2026

Revenue growth	EBITDA margin	EBT margin
15-23%	19-21%	11-13%

Ambitions towards 2030

6-9% annual growth during the period to 2030:	EBITDA margin of 20-22% in 2030:	EBT margin of 12-14% in 2030:
≈ DKK 4.5 billion	≈ DKK 950 million	≈ DKK 600 million

EBITDA and EBITDA margin performance



Healthcare 40%
- Medical devices
- Pharmaceutical packaging
- Ergonomics and safety

Cleantech 27%
- Renewable energy
- Energy reduction
- Insulation products

Foodtech 13%
- Livestock housing ventilation
- Measuring equipment

Other 20%
- Furniture
- Specialist vehicles
- Maritime products
- Defence industry

Quoted Equities

New entry since January

KRONES

- Global market leader in filling and packaging technology for beverages.
- Newly launched Ingeniq line is a fully automated line system for filling still water (>50% of end market demand) at a 10% lower TCO
- Growth driven by population growth, urbanisation and higher requirements for food quality and sustainability
- Market cap: ca. € 4.3B
- Portfolio entry: 2026

P/E	4y EPS CAGR	ROE	Debt ratio
10.3x	21%	14%	-0.8x

source: P/E, ROE & debt ratio based on 12-month forward Bloomberg estimates at 30 June 2026

Quoted Equities

New entry

KRONES

Solutions beyond tomorrow – Our strategic focus

Filling and Packaging Technology

Integrated packaging solutions

Process Technology

Food and beverage innovation

Intralogistics

Fully automated, flexible intralogistics

Superior services

Sustainability

Digitalization

Quoted Equities

New entry

KRONES

Product transformation: Process Technology
Megatrends persist and continue to shape our strategy

Fermentation technology	Water Technology	Sustainable Solutions
Proteins from advanced fermentation	Water treatment & water design	Energy efficiency & waste minimization

CAGR ~14%	CAGR >6%	CAGR >20%
InsightAce Analytic 2023 - 2031	Precedence Research 2024 - 2032	Fortune Business Insights 2024 - 2032

Market potential until 2030, bn €, assuming ~1,000 € investment to reduce 1t CO_2



Quoted Equities

Exit Kerry Group - € 13B market cap, 2nd largest in portfolio

Quoted Equities

Exit Melexis - +1,300% total return since first purchase

Quest FOR GROWTH

8.7% Venture & growth capital

Cleantech	Digital	Health
QPINCH 2.2%	sensolus 1.9%	confo therapeutics 0.7%
DMC 1.50%	Gradyent 1.8%	**0.7%**
3.8%	fruitcore robotics 1.0%	
	EclecticIQ 0.9%	
	NGDATA 0.04%	
	5.6%	

Undisclosed valuation changes in V&G Capital: -1.4%

Quest FOR GROWTH

VENTURE & GROWTH CAPITAL

Participations	Sector	Buy/sells (amount) since 31/12/2025	Currency	Valuation in base currency	Valuation in EUR	In % of Net Asset Value
CONFO THERAPEUTICS	Health		EUR	820,000	820,000	0.75%
DMC	Cleantech	USD 109,750	USD	1,831,749	1,607,644	1.46%
ECLECTICIQ	Digital	EUR 100,000	EUR	980,673	980,673	0.89%
FRUITCORE ROBOTICS	Digital	EUR 74,876	EUR	1,147,964	1,147,964	1.04%
GRADYENT	Digital		EUR	1,992,480	1,992,480	1.81%
NGDATA	Digital		EUR	46,728	46,728	0.04%
QPINCH	Cleantech		EUR	2,369,804	2,369,804	2.16%
SENSOLUS	Digital		EUR	2,078,082	2,078,082	1.89%
					11,043,374	**10.05%**

Change in valuation venture & growth capital	EUR		-1,502,501	-1.37%

Venture & Growth Capital

2026 H1 – Investments

- **$ 110K** follow-on investment in **DMC Biotechnologies** (USA)
  - Part of $7.8M round closed in April 2026
  - Co-investment with Capricorn SCF
- **€ 100K** follow-on investment in **EclecticIQ** (Nederland)
  - Part of € 1.75M internal round
  - Co-investment with Capricorn Digital Growth Fund
- **€ 75K** follow-on investment in **fruitcore robotics** (Germany)
  - Part of € 2.85M internal round
  - Co-investment with Capricorn Fusion China Fund

- In the first quarter of 2026, some of our direct and indirect portfolio companies in the digital segment suffered from the "SaaSpocalypse".
- Investors are worried that agentic AI (autonomous systems capable of executing workflows on their own) could make traditional software-as-a-service (SaaS) applications obsolete.
- Public markets have reacted as if that future is already underway, and as a result, valuation multiples of several software companies have dropped significantly in Q1 2026, which heavily impacted the peer group multiples applied to Quest for Growth's portfolio companies and thereby their valuations.
- Some companies had already recovered by the second quarter, though we are not yet seeing a general recovery to 2025 levels.

Quest FOR GROWTH

31.3%
Venture & growth funds

Cleantech

Capricorn SCF

- DMC
- ECONIC
- QPINCH
- TRILLIUM Renewable Chemicals
- VIROVET Livestock Solutions
- VOID. Technologies
- ZEOPORE

7.2%

Digital

Capricorn ICT Arkiv

- ARKITE
- NGDATA
- sensolus

2.6%

Capricorn Digital Growth Fund

- AZUMUTA
- bingli
- chainels
- DEO.care
- EclecticIQ
- Gradyent
- Minze health at home
- neotiv
- StoryChief
- Thryve
- Trendtracker
- VoxelSensors
- ROCSYS
- ZOZIO
- CONXAI

10.6%

Health

Capricorn Healthtech Fund

- confo therapeutics
- iSTAR MEDICAL
- Mainstay Medical

5.4%

Capricorn Healthtech Fund II

- Aspect Analytics
- oska
- XYALL

3.1%

Diversified

Capricorn Fusion China Fund

- fruitcore robotics
- spectricity
- XenomatiX True solid state lidar
- XIAN-THIEBAUT

2.2%

Andere

- F
- EQT Life Sciences

0.2%

Quest FOR GROWTH

VENTURE & GROWTH FUNDS

		Last valuation date	Capital calls (+) / distributions (-) since 31/12/2025	Currency	Valuation in base currency	Valuation in EUR	In % of Net Asset Value
Capricorn Partners							
CAPRICORN DIGITAL GROWTH FUND	Digital	30/06/2026	EUR 2,400,000	EUR	11,641,299	11,641,299	10.60%
CAPRICORN FUSION CHINA FUND	Diversified	30/06/2026	EUR 229,983	EUR	2,372,127	2,372,127	2.16%
CAPRICORN HEALTHTECH FUND	Health	30/06/2026		EUR	5,957,342	5,957,342	5.42%
CAPRICORN HEALTHTECH FUND II	Health	30/06/2026	EUR 2,503,899	EUR	3,370,847	3,370,847	3.07%
CAPRICORN ICT ARKIV	Digital	30/06/2026	EUR -1,506,500	EUR	2,816,442	2,816,442	2.56%
CAPRICORN SCF	Cleantech	30/06/2026	EUR 800,000	EUR	7,925,812	7,925,812	7.21%
Other funds							
FORTINO VENTURES III	Digital	30/06/2026	EUR 195,586	EUR	195,586	195,586	0.18%
LIFE SCIENCES PARTNERS IV	Health	31/03/2026		EUR	62,000	62,000	0.06%
						34,341,454	**31.26%**

Venture & Growth Funds

2026 H1 – Investments

Capital calls

▪ Capricorn Digital Growth Fund	€ 2.4 million	New investments: Conxai & Rocsys
▪ Capricorn Fusion China Fund	€ 0.2 million	Follow-on investments: Spectricity
▪ Capricorn Healthtech Fund II	€ 2.5 million	New investments: Xyall & Oska Health (& EndoTools Q3)
▪ Capricorn SCF	€ 0.8 million	Follow-on investments: DMC, Zeopore & Econic
▪ Fortino Ventures III	€ 0.2 million	New investments: mkind, Polysense.ai, Birdsview

Capital distributions

▪ Capricorn ICT Arkiv	€ 2.0 million	Sale Icometrix (of which € 500K as a dividend)

Venture & Growth Funds

2026 H1 – Investments Digital Growth Fund

Conxai scales agentic AI to automate complex construction workflows with fresh capital from BayBG and Capricorn Partners

7 April 2026

€ 2.0M investment in Conxai (Germany)

Rocsys unveils world's first multi-bay hands-free charging solution to help robotaxi fleets scale, and raises $13 million Series A extension

30 April 2026

€ 3.5M investment in Rocsys (the Netherlands)

Venture & Growth Funds

2026 H1 – Investments Capricorn Healthtech Fund II

Capricorn Partners and Swiss Health Co-Lead €11M Round to Scale AI-Hybrid Care Platform Oska Health Across Europe

26 February 2026 →

€ 2.0M investment in Oska Health (Germany)

Medtech innovator Xyall closes € 7.6 million financing round to globally roll out its unique high-tech molecular pathology laboratory solutions

11 February 2026 →

€ 3.0M investment in Xyall (the Netherlands)

Capricorn Healthtech Fund II increased its fund size from € 62 million at end of 2025 to € 89 million end of June.

Venture & Growth Funds

2026 Q3 – Investments Capricorn Healthtech Fund II



Capricorn Partners and MGFO Co-Lead € 20 million Round for Endo Tools to transform gastrointestinal care and obesity management across the U.S.

16 July 2026

Confidential

€ 5.0M investment in EndoTools (Belgium)

€ 3.0M investment in medtech (France)

Venture & Growth Funds

2026 Q2 – Investments Fortino Ventures III



Fortino Ventures
2,795 followers
3w

Today, we are excited to announce our investment in mkind, joining their €3M Pre-Seed round led by Lucid Capital to push the industrial robotics AI frontier out of Europe.

Michael made a point that stuck with us: capability follows the work. Europe still has world-class manufacturers, but rising labour costs and an aging workforce are forcing a choice between outsourcing and automation - and today's automation is too rigid for high-mix production.

That's the gap that mkind closes: Programming a robot for one part takes a specialist 4-6 weeks; with mkind you scan it and get a working program in <30 minutes, no robotics expertise needed. An expert colleague on the factory floor, built on cutting edge robotics research - physical AI made in Europe
Backing Michael Sauer, Christoph Willibald & Gabriele Tiboni and the team on their bet: Europe will be a manufacturing powerhouse again powered by industrial robotics AI.

Patrick Hermann
Luisa Buche
Lucid Capital
Possible Ventures
Kvanted
Thomas Wolf

€ 0.25M investment in mkind (Germany)



Fortino Ventures
2,795 followers
1w

Very keen to be backing Polysense in their journey to drastically reduce waste in food manufacturing.

Food production faces a structural trade-off: rigid automation that can't adapt to high-mix lines, or manual inspection that doesn't scale. Polysense turns waste reduction and yield optimization into a software problem, not a hardware one.

Very happy to be investing alongside Felix Capital, Syndicate One, 100IN. Also great to see some amazing angels as early believers, TechWolf founders (Andreas, Jeroen & Mikaël), and Peter Hinssen amongst many others.

Thrilled to support Yarne De Munck, Jarne Bogaert & Lucas Van Dijck and the team in their global ambitions.

€ 2.5M investment in Polysense.ai (Belgium)



Fortino Ventures
2,795 followers
1w

We are excited to announce our investment in Birdsview.com alongside Newion.

Birdsview is going after the $50Bn customer retention market for online brands such as Lush, Atletica, and 4mybaby. Their digital worker, "Avys," auto-generates hyper-personalized campaigns towards every customer at the right point in time and has proven to be significantly more effective than traditional approaches.

Looking forward to working with Ozan, Tim and Razvan, whose background in data science and AI engineering for retail makes them the perfect team to build a world-class company in this space.

Wouter Filip Patrick Lukas Luisa Louise Hugh Nicolas

€ 1.25M investment in Birdsview.com (Germany)

Venture & Growth Funds

Largest positions Direct + Indirect

Co-investment with Capricorn Healthtech Fund

Co-investors:

Co-investment with Capricorn ICT Arkiv

Co-investors:

Co-investment with Capricorn Digital Growth Fund

Co-investors

Quest for Summer

Why invest in Quest for Growth?

Diversified segments

1. Investments in quoted small- and midcaps
2. Investments in venture & growth funds
3. Direct investments in venture & growth capital

Diversified themes

1. Cleantech
2. Healthtech
3. Digitalisation

Daily tradable access

Favourable tax status (public PRIVAK)

Significant discount to net asset value

Capricorn Partners NV
Lei 19 - 3000 Leuven. Belgium
+32 16 28 41 00
info@capricorn.be